Stay updated on Pembrolizumab After Non-ablative Radiation in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab After Non-ablative Radiation in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab After Non-ablative Radiation in NSCLC Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedLocations now include Ohio as a study site; the Ohio Locations entry was removed and the HHS Vulnerability Disclosure footer link was deleted.SummaryDifference0.2%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedRevision: v3.3.2 replaces v3.3.1 on the page; no study content, eligibility criteria, or results are changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check44 days agoChange Detected- The page shows an updated revision number from v3.2.0 to v3.3.1, with no changes to study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange DetectedRemoved the informational funding/operating-status notice that previously appeared at the top; this banner does not modify study details, eligibility criteria, or contact information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check65 days agoChange DetectedThe page shows minor formatting and layout tweaks with no changes to core content such as eligibility criteria, outcomes, or study arms. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check94 days agoChange DetectedMajor update: new operating-status notice and a version upgrade to v3.2.0, replacing the prior v3.1.0.SummaryDifference3%

Stay in the know with updates to Pembrolizumab After Non-ablative Radiation in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab After Non-ablative Radiation in NSCLC Clinical Trial page.